| Literature DB >> 35167423 |
Ilaria Gandoglia1, Laura Strada1, Anna Poleggi2, Antonio Castaldi3, Massimo Del Sette4, Emilio Di Maria5,6.
Abstract
Creutzfeldt-Jakob disease (CJD) is usually sporadic, but 10-15% of cases are caused by autosomal-dominant pathogenic variants in the prion protein gene (PRNP). A few PRNP variants show low penetrance. We report the case of a 64-year-old man, admitted to the ward with acute onset of aphasia; death occurred 6 weeks later. Brain MRI, EEG pattern and brain pathology were consistent with CJD diagnosis. Genetic analysis revealed a heterozygous V203I variant. We summarized the key clinical findings in patients carrying the V203I variant who were described to date. We also discuss the hypothesis as to whether V203I is a risk factor for CJD rather than a Mendelian disease-associated variant, as well as the possible implications of such hypothesis in the clinical scenario.Entities:
Keywords: PRNP; genotype; penetrance; prion disease; review; risk factor; stroke-like onset
Mesh:
Substances:
Year: 2022 PMID: 35167423 PMCID: PMC8855849 DOI: 10.1080/19336896.2022.2035479
Source DB: PubMed Journal: Prion ISSN: 1933-6896 Impact factor: 3.931
Figure 1.The MRI axial DWI sequence shows signal hyperintensity involving the right frontal, the left frontal and parietal cortical areas (known as cortical ribbon sign); insular cortex (especially on the left) and left corpus striatum are also involved. Areas of interest are highlighted by arrows.
Clinical features of CJD patients carrying the PRNP V301I variant (nr = not reported)
| Publication | Peoc’h 2000 [ | Jeong 2010 [ | Shi 2013 [ | Komatsu 2014 [ | Cistaro 2017 [ | Kovacs 2017 [ | Kovacs 2017 [ | Kovacs 2017 [ | Tang 2018 [ | Present case |
|---|---|---|---|---|---|---|---|---|---|---|
| V301I genotype | Val/Ile | Val/Ile | Val/Ile | Ile/Ile | Val/Ile | Val/Ile | Val/Ile | Val/Ile | Val/Ile | Val/Ile |
| M129V genotype | Met/Met | Met/Val | Met/Met | Met/Met | nr | Met/Met | Met/Met | Met/Met | Met/Met | Met/Met |
| Sex | M | F | M | F | F | M | F | M | F | M |
| Family history | negative | nr | negative | negative | negative | nr | nr | nr | nr | negative |
| Age at diagnosis | 69 | 66 | 80 | 73 | 48 | 76 | 71 | 69 | 61 | 64 |
| Duration of disease | 35 days | 2 months | 2 months | 24 months | nr | 7 months | 7 months | 2 months | 7 months | 6 weeks |
| Cognitive symptoms | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes |
| Behavioural symptoms | yes | yes | no | no | nr | nr | nr | nr | yes | yes |
| Psychotic symptoms | yes | no | no | no | nr | yes | yes | no | no | yes |
| Ataxia | yes | yes | yes | no | yes | yes | no | yes | nr | yes |
| Tremor | yes | yes | yes | no | nr | yes | yes | yes | nr | yes |
| Rigidity | no | yes | yes | no | nr | yes | yes | yes | nr | yes |
| Brain MRI | nr | typical | typical | typical | typical | nr | typical | nr | typical | typical |
| EEG | typical | nr | typical | typical | typical | typical | typical | typical | moderate abnormality (not specified) | typical |
| CSF | nr | nr | 14.3.3 | 14.3.3 and tau | tau | 14.3.3 | 14.3.3 | 14.3.3 | negative | 14.3.3 and tau |
| Pathology | nr | typical | nr | typical | nr | prominent astrocytic | prominent astrocytic | prominent astrocytic | nr | typical |